Chemo Experts, the easiest way to learn about cancer treatment
Find a Treatment:
Cancer Types

Treatment Name: Cisplatin + Pemetrexed (Alimta®) + Bevacizumab

Cisplatin + Pemetrexed (Alimta®) + Bevacizumab is a Chemotherapy Regimen for Lung Cancer, Non-Small Cell Lung Cancer (NSCLC)

Thank you for visiting our Cisplatin + Pemetrexed (Alimta®) + Bevacizumab page.

  • If you are interested in seeing the full treatment regimen page for Cisplatin + Pemetrexed (Alimta®) + Bevacizumab sooner rather than later, please cast your vote for Cisplatin + Pemetrexed (Alimta®) + Bevacizumab.
  • Votes from users like you are important as they help us prioritize the order in which we build our content. The more requests we receive, the faster we will build it!

While we work on uploading the pages that matter to you most, we hope that links to journal article references for Cisplatin + Pemetrexed (Alimta®) + Bevacizumab shown below will prove useful in the meantime.

Thank you for your continued support!

The ChemoExperts Team


1) Barlesi F, Scherpereel A, Rittmeywr A, et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in 4 advanced nonsquamous non-small cell lung cancer: AVAPERL. J Clin Oncol. 2013;31:3004-3011.

Created: March 13, 2019 Updated: March 13, 2019

What is Lung Cancer, Non-Small Cell Lung Cancer (NSCLC)?

What is Non-Small Cell Lung Cancer?
A disease of the tissue found in the lung.  Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Known causes include smoking and exposure to environmental toxins.  The stage of NSCLC can vary at diagnosis and throughout treatment.  Stages include stage I, II, III, and IV.  The effectiveness of the treatment may depend upon the stage at diagnosis.

NOTE: Treatment Options listed below are not all-inclusive. Other treatments may be available. ChemoExperts provides drug information and does not recommend any one treatment over another. Only your Doctor can choose which therapy is appropriate for you.

Common Cisplatin + Pemetrexed (Alimta®) + Bevacizumab (Avastin®) starting doses


  • Cisplatin 75 mg/m2 intravenous (I.V.) infusion over 60 minutes on Day 1
  • Pemetrexed 500 mg/m2 I.V. infusion over 10 minutes on Day 1
  • Bevacizumab 7.5 mg/kg I.V. infusion over 90 minutes on Day 1 of Cycle 1
    • then over 60 minutes for Cycle 2, if no infusion reactions occur
    • then over 30 minutes for Cycles 3 and on, if no infusion reactions occur


  • Pemetrexed 500 mg/m2 I.V. infusion over 10 minutes on Day 1
  • Bevacizumab 7.5 mg/kg I.V. infusion over 30 minutes on Day 1